INF2 and lung adenocarcinoma: Thus, we searched for INF2 mutants in ECa and other cancers and noted three cancer-associated INF2 mutants with deletions or impact in 940–1249 aa of INF2, including two missense mutants (L1114I, two samples, one in ECa and the other in liver hepatocellular carcinoma; T1179M, two samples, one in ECa and the other in sarcoma) and one nonsense mutation (V530X, 13 samples, two in ECa, one in lung adenocarcinoma, seven in stomach adenocarcinoma, and three in colorectal adenocarcinoma) (Supplementary Fig. 4G).